⚕ GalenOps CRO console
← SITE013 (USA)

SITE013-0372

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE013 (USA) (Dr. Clarke) · consented 2023-05-13
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 7); relationship: N

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-21 (study day 122); relationship: N

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-11 (study day 234); relationship: N

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-07-03 (study day 408); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-08-14 (study day 450); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-08-19 (study day 455); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-09-12 (study day 479); relationship: N

severe serious reported 2026-08-18

Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-12-07 (study day 565); relationship: N; serious criteria: life-threatening

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.